Phase 4 N=2,776 Study of Tomography of Nephrolithiasis Evaluation
Urolithiasis
Primary: High Risk Diagnosis With Complication — 6; 3; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=104 Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones
Urolithiasis · Urinary Lithiasis · Kidney Calculi
Primary: Stone Clearance — 76 participants
Phase 4 N=512 Tamsulosin for Urolithiasis in the Emergency Dept
Ureterolithiases
Primary: Proportion of Patients Passing Their Stone Within 28 Days by Self Report — 128; 113 Participants
Phase 2 N=10 The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
Cystinuria
Primary: 24hr Urine Measurements of the Effect of SGLT-2 Inhibitor Therapy on Cystine Production in Urine in Patients With Cystinuria — 999.3 24hr urine cystine concentration…
Phase 2 N=16 Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Hyperoxaluria · Nephrolithiasis
Primary: Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion — -13.92 mg/day
N/A N=108 Trial Assessing Renal Damage During Ureteroscopy
Nephrolithiasis
Primary: Change in Kidney Injury Molecule-1 (KIM-1) — 0.01077; 0.01228; 0.0246; 0.02413 ng/ml
N/A N=234 Intraoperative Cone-beam CT for Percutaneous Nephrolithotomy
Nephrolithiasis
Primary: "Second Look" Rate — 4; 56; 56; 118 Participants — p=<0.01
Phase 2 N=13 Treatment for Calcium Phosphate Kidney Stone Disease
Calcium Phosphate Kidney Stones
Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units
N/A N=13 Effect of Cola on Urinary Stone Risk Factors
Kidney Stone
Primary: The Plasma and Urine Parameters — 6800; 6800; 3700; 3700 mg per dL
N/A N=171 A Comparison of Ureteroscopic Treatment of Nephrolithiasis With and Without Moses Technology
Nephrolithiasis
Primary: Operative Time — 36; 37 minutes
N/A N=58 Obesity and Endogenous Oxalate Synthesis
Obesity
Primary: Urinary Oxalate Excretion — 24 mg/day
Phase 3 N=416 Hydrochlorothiazide for Kidney Stone Recurrence Prevention
Nephrolithiasis
Primary: Number of Participants With Stone Recurrences — 60; 62; 61; 49 Participants
Phase 2 N=239 Study of Silodosin to Facilitate Passage of Urinary Stones
Ureteral Calculi · Kidney Stones · Urolithiasis
Primary: Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures…
N/A N=74 The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic
Ureteral Calculi
Primary: Time in Days From Diagnosis to Stone Passage. — 5; 13 Days
N/A N=30 Evaluation of a Nonopioid Recovery Pathway Following Surgery for Kidney Stones
Nephrolithiasis
Primary: Protocol Feasibility — 14; 10 Participants
Phase 3 N=19 Phentermine/Topiramate for Uric Acid Stones
Obesity · Uric Acid Stones · Type 2 Diabetes Mellitus in Obese
Primary: Kidney Stone Size (mm^3) Determined by Non-contrast CAT Scan — 6540; 4650; 3120; 5041 mm^3
N/A N=1,658 Prevention of Urinary Stones With Hydration
Urinary Stones
Primary: Number of Participants With a Symptomatic Stone Event — 154; 165 Participants
Phase 4 N=17 Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy
Renal Calculus · Kidney Stones
Primary: Pain 'Right Now' — 1.0; 0.9 units on a scale
Phase 2 N=99 Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
Hyperuricosuria · Kidney Stones
Primary: Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion — -58.6; -36.4; -12.7 percent change — p=<0.001
N/A N=100 Medical Expulsive Therapy of Single Distal Ureteral Stones
Ureteral Calculi
Primary: Number of Participants With Stone Expulsion — 39; 40 Participants
N/A N=70 Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
Kidney Stones
Primary: Kidney Stone Clearance Rate — 61.9; 75.8 mm^2/min
Phase 2 N=20 Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
Cystinuria · Nephrolithiasis, Calcium Oxalate
Primary: 24 Hour Urine Supersaturation of Calcium Oxalate (CaOx) — 1.83; 1.83; 1.87; 1.78 KJoules/mol — p=0.32
Phase 4 N=90 Narcotic-Free Percutaneous Nephrolithotomy
Nephrolithiasis
Primary: Visual Analog Scale (VAS) Pain Scores — 4.5; 5; 1; 1 score on a scale
Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
N/A N=53 Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis
Kidney Stone
Primary: Time of Stone Passage — 68.8; 19.0 hours
N/A N=46 Effects of Flexible Ureteroscopy on Renal Blood Flow
Circulatory; Change
Primary: Peak Systolic Velocities (PSV) Measurement by Renal Doppler Ultrasound (US) Examination Evaluating the Effects of Flexible Ureteroscopy (F-URS) on Renal Blood Flow by…
N/A N=20 Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings
Stone Clearance
Primary: Stone Clearance — 6; 6; 3; 4 Participants
N/A N=127 The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
Kidney Stones · Ureteral Stones
Primary: Stone Passage — 18; 21 participants
N/A N=240 Antibiotic Selection Using Next Generation Sequencing vs Urine Culture
Kidney Stone · Renal Stone · Infection, Bacterial
Primary: Incidence of Infection Post Surgery — 0; 7 participants
N/A N=264 Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone
Kidney Stones
Primary: Radiation Exposure (Dose-Length-Product) at Baseline — 293.5; 482.1; 915.99 mGy*cm